Mon, Jan 26, 2015, 10:40 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

nonfollower3 6 posts  |  Last Activity: Dec 9, 2014 5:15 PM Member since: Aug 12, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Options, stock not looking good

    by bioimmunomabman Dec 8, 2014 10:17 AM
    nonfollower3 nonfollower3 Dec 9, 2014 5:15 PM Flag

    I don't doubt that speculative money is piling into the newer more attractive bio tech but I think ADC is moving into a maturity phase where the income will start coming in.

    Stocks with income can't be manipulated as easily because the income can be analyzed and a proper share price projected. Focus and money might be flowing to the new tech but that doesn't mean you can't make money here. I'm hoping for more stability and steady growth once the income gets higher and continues to increase.

    Sentiment: Buy

  • Reply to

    CBST buyout for $8B

    by slumdawg2011 Dec 7, 2014 3:55 PM
    nonfollower3 nonfollower3 Dec 7, 2014 7:10 PM Flag

    I guess that company has a promising antibiotic that may be the only game in town in just a few short years from now.

  • Reply to

    Awfully Quiet!

    by biotechbeagle Nov 22, 2014 10:43 AM
    nonfollower3 nonfollower3 Nov 24, 2014 12:33 PM Flag

    last 3 month price movement for imgn vs sgen are identical...but I dont' really want to look at the longer term charts ;)

    Sentiment: Buy

  • Reply to

    Awfully Quiet!

    by biotechbeagle Nov 22, 2014 10:43 AM
    nonfollower3 nonfollower3 Nov 23, 2014 11:18 AM Flag

    Someone on IV mentioned the possibility that we might be in a quiet period. My feeling is that the company is in a stage where there's not alot to issue PRs but they are rolling through the testing and the paperwork involved with the filings and human testing.

    While I'm sure the management can't ward off a company buying up shares on the open market that is the main reason they need to keep the outstanding shares high. I'm not sure IMGN's business model would even lend itself to being taken out in a hostile bid but I'm pretty sure with just a small number of shares available for trade that it would not be possible without some kind of an announcement like Roche coming forward and offering 25 per share.

    just waking up and not thinking clearly so take my thoughts for what they're worth.

    Sentiment: Buy

  • nonfollower3 nonfollower3 Nov 13, 2014 6:09 PM Flag

    i guess the same factors that make IMGN a great place to work annoy the shareholders. looking at the number of shares voting against the recommendation is something like 1.7million vs 75 million. Theres no chance us little guys amount to very much when things come down to a vote.

  • Reply to

    Why doesn't Immunogen do a press release?

    by bigbaldhead5 Oct 29, 2014 9:17 AM
    nonfollower3 nonfollower3 Oct 29, 2014 10:47 AM Flag

    I would have to disagree. Afterhours action is not indicative. Since market makers don't participate after hours, the price floats based off buy sell orders. If that ventana item was really something important you would see it affect the share price in today's action during actual trading.

    It's important to ventana, because IMGN probably paid them something either upfront or with royalties or both. Technically, a cash outlay should be material though so I'm not sure what's happening.

    Sentiment: Buy

IMGN
6.47+0.14(+2.21%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.